Item


Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection

Prostate Specific Antigen (PSA) is the most commonly used serum marker for prostate cancer (PCa), although it is not specific and sensitive enough to allow the differential diagnosis of the more aggressive tumors. For that, new diagnostic methods are being developed, such as PCA-3, PSA isoforms that have resulted in the 4K score or the Prostate Health Index (PHI), and PSA glycoforms. In the present study, we have compared the PHI with our recently developed PSA glycoform assay, based on the determination of the α2,3-sialic acid percentage of serum PSA (% α2,3-SA), in a cohort of 79 patients, which include 50 PCa of different grades and 29 benign prostate hyperplasia (BPH) patients. The % α2,3-SA could distinguish high-risk PCa patients from the rest of patients better than the PHI (area under the curve (AUC) of 0.971 vs. 0.840), although the PHI correlated better with the Gleason score than the % α2,3-SA. The combination of both markers increased the AUC up to 0.985 resulting in 100% sensitivity and 94.7% specificity to differentiate high-risk PCa from the other low and intermediate-risk PCa and BPH patients. These results suggest that both serum markers complement each other and offer an improved diagnostic tool to identify high-risk PCa, which is an important requirement for guiding treatment decisions

This work was supported by the Spanish Ministerio de Economia y Competitividad (CDTI grant IDI20130186 and grant BIO 2015-66356-R), by the Generalitat de Catalunya, Spain (grant 2014 SGR 229), and by Roche Diagnostics (Barcelona, Spain). We thank Mireia Lopez-Siles for her support with GraphPad Prism 5

International Journal of Molecular Sciences, 2017, vol. 18, núm. 4, p. 845

MDPI (Multidisciplinary Digital Publishing Institute)

Author: Ferrer-Batallé, Montserrat
Llop Escorihuela, Esther
Ramírez, Manel
Aleixandre i Cerarols, Rosa Núria
Sáez Zafra, Marc
Comet i Batlle, Josep
Llorens Duran, Rafael de
Peracaula Miró, Rosa
Date: 2017 April 17
Abstract: Prostate Specific Antigen (PSA) is the most commonly used serum marker for prostate cancer (PCa), although it is not specific and sensitive enough to allow the differential diagnosis of the more aggressive tumors. For that, new diagnostic methods are being developed, such as PCA-3, PSA isoforms that have resulted in the 4K score or the Prostate Health Index (PHI), and PSA glycoforms. In the present study, we have compared the PHI with our recently developed PSA glycoform assay, based on the determination of the α2,3-sialic acid percentage of serum PSA (% α2,3-SA), in a cohort of 79 patients, which include 50 PCa of different grades and 29 benign prostate hyperplasia (BPH) patients. The % α2,3-SA could distinguish high-risk PCa patients from the rest of patients better than the PHI (area under the curve (AUC) of 0.971 vs. 0.840), although the PHI correlated better with the Gleason score than the % α2,3-SA. The combination of both markers increased the AUC up to 0.985 resulting in 100% sensitivity and 94.7% specificity to differentiate high-risk PCa from the other low and intermediate-risk PCa and BPH patients. These results suggest that both serum markers complement each other and offer an improved diagnostic tool to identify high-risk PCa, which is an important requirement for guiding treatment decisions
This work was supported by the Spanish Ministerio de Economia y Competitividad (CDTI grant IDI20130186 and grant BIO 2015-66356-R), by the Generalitat de Catalunya, Spain (grant 2014 SGR 229), and by Roche Diagnostics (Barcelona, Spain). We thank Mireia Lopez-Siles for her support with GraphPad Prism 5
Format: application/pdf
ISSN: 1422-0067
Document access: http://hdl.handle.net/10256/13861
Language: eng
Publisher: MDPI (Multidisciplinary Digital Publishing Institute)
Collection: MINECO/PE 2016-2018/BIO2015-66356-R
Reproducció digital del document publicat a: http://dx.doi.org/10.3390/ijms18040845
Articles publicats (D-B)
Is part of: International Journal of Molecular Sciences, 2017, vol. 18, núm. 4, p. 845
Rights: Attribution 4.0 Spain
Rights URI: http://creativecommons.org/licenses/by/4.0/es/
Subject: Pròstata -- Càncer -- Diagnòstic
Prostate -- Cancer -- Diagnosis
Pròstata -- Càncer
Prostate -- Cancer
Glicosilació
Glycosylation
Title: Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection
Type: info:eu-repo/semantics/article
Repository: DUGiDocs

Subjects

Authors